

FDA Updates Warning for Two Classes of Antidepressants

The FDA is requiring manufacturers of two types of antidepressants, selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors, to update their drug warnings with information on neuroleptic malignant syndrome. The agency sent letters to numerous drugmakers, requesting the labeling updates and invoking section 505(o)(4) of the Food, Drug and Cosmetic Act that gave it new powers to require safety-related labeling changes for drugs under the FDA Amendments Act.

Drug Industry Daily

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright 2009 by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.